SAB Biotherapeutics Total Liabilities and Share Holders Equity 2021-2025 | SABS

SAB Biotherapeutics total liabilities and share holders equity from 2021 to 2025. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.

SAB Biotherapeutics Total Liabilities and Share Holders Equity 2021-2025 | SABS

SAB Biotherapeutics total liabilities and share holders equity from 2021 to 2025. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$217.3B
Amgen (AMGN)$160.8B
Gilead Sciences (GILD)$136.6B
Vertex Pharmaceuticals (VRTX)$120.6B
Bristol Myers Squibb (BMY)$96B
CSL (CSLLY)$78.5B
GSK (GSK)$78.4B
Regeneron Pharmaceuticals (REGN)$59.2B
Alnylam Pharmaceuticals (ALNY)$42.1B
Argenex SE (ARGX)$35.4B
BioNTech SE (BNTX)$27B
Royalty Pharma (RPRX)$20B
Insmed (INSM)$19.8B
Biogen (BIIB)$18.8B
Illumina (ILMN)$15.3B
Genmab (GNMSF)$14.2B
Genmab (GMAB)$14B
Incyte (INCY)$13.4B
Moderna (MRNA)$12.4B
Exelixis (EXEL)$12.2B
BioMarin Pharmaceutical (BMRN)$11.2B
QIAGEN (QGEN)$10.7B
Ascendis Pharma (ASND)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Exact Sciences (EXAS)$10.1B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$8.1B
Roivant Sciences (ROIV)$7.8B
Regencell Bioscience Holdings (RGC)$7.6B